Clareo Health | Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
Age
18–58
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of relapsing remitting MS (RRMS) or onset of secondary progressive MS (SPMS)
RRMS and SPMS subjects must have evidence of ongoing disease activity within 12 months of enrollment.
All male and female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for at least 6 months after their last dose of study treatment
You may not be if
A MS relapse that has occurred within the 90 days prior to Day 1/Baseline and/or the subject has not stabilized from a previous relapse prior to Screening
Previous history of clinically significant disease.
Plans to undergo elective major procedures/surgeries at any time during the study.
Treatment with any investigational MS drugs within 3 weeks or 5 times the half life (whichever is longer) prior to Day 1/Baseline
RRMS subjects with any history of inadequate response to any approved interferon β preparation
History of human immunodeficiency virus (HIV), hepatitis C virus antibody, or hepatitis B virus
History or evidence of drug or alcohol abuse within 2 years prior to randomization
